SL
ACHL

Siren LLC’s Achilles Therapeutics ACHL Stock Holding History

Siren LLC’s Portfolio ACHL Stock Details ACHL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-755,375
Closed -$861K – 140
2024
Q4 		$861K Hold
755,375
– – 0.04% 103
2024
Q3 		$770K Buy
+755,375
New +$605K 0.04% 101

Other funds holding ACHL

XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
BAM
Brave Asset Management Summit, New Jersey $467M AUM 33.05% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $3.65B AUM 41.88% 1-Year Est. Return

Siren LLC's ACHL Position: Q1 2025 in Review

Siren LLC sold out of Achilles Therapeutics (ACHL) in Q1 2025, closing a stake of 755,375 shares — an estimated $861K sold.

Siren LLC first reported a position in ACHL in Q3 2024 and held it in 2 quarters. The position peaked at $861K in Q4 2024. 6 funds tracked by Wall St. Rank hold ACHL as of Q1 2025.

  • Siren LLC reported no remaining Achilles Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Siren LLC sold 755,375 Achilles Therapeutics shares in Q1 2025, an estimated $861K.
  • Siren LLC first reported a position in Achilles Therapeutics in Q3 2024 and held it in 2 quarters.
  • Siren LLC's Achilles Therapeutics position peaked at $861K in Q4 2024.
  • 6 funds tracked by Wall St. Rank held Achilles Therapeutics as of Q1 2025.

Based on Siren LLC's 13F filing for Q1 2025, filed 14 May 2025.